Uso de canabinoides no tratamento de distúrbios neurológicos em idosos
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Identificar os estudos científicos sobre o uso de derivados canabinoides no tratamento de distúrbios neurológicos por pacientes idosos. Métodos: Revisão integrativa da literatura nas plataformas de dados PubMED, Portal Regional Biblioteca Virtual em Saúde, e Periódicos CAPES, realizada entre agosto e dezembro de 2023. Foram utilizados descritores do Medical Subject Headings: "aged", "therapeutic", "cannabis”, "parkinson's Disease”, "epilepsy", "dementia", "bipolar disorders" e "depression" combinados com o operador booleano “AND”. Foram incluídos trabalhos publicados no período de 2012 a 2022, sem restrições de idioma, excluindo duplicatas e revisões. A triagem inicial foi feita por dois avaliadores independentes e divergências foram resolvidas em consenso. Resultados: A amostra final foi composta de 25 artigos, os quais descreveram uso de canabinoides para tratamento de Doença de Parkinson, Alzheimer, transtorno de estresse pós-traumático, depressão, ansiedade e queixas de sono, doenças crônicas (câncer, glaucoma e HIV/AIDS), depressão, demência frontotemporal, transtorno bipolar, esclerose múltipla, prurido neuropático refratário na esclerose lateral amiotrófica e epilepsia. Considerações finais: A discussão sobre o uso de canabinoides tem crescido, evidenciando benefícios em vários distúrbios neurológicos e melhoria na qualidade de vida em idosos, mas ainda carece de estudos de sua eficácia e segurança.
##plugins.themes.bootstrap3.article.details##
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
2. BRASIL. Ministério da Saúde. Saúde da pessoa idosa. 2022. Disponível em:
3. BOEHNKE KF, et al. Cannabidiol Product Dosing and Decision-Making in a National Survey of Individuals with Fibromyalgia. The Journal of Pain, 2022. Disponível em:
4. BONN-MILLER MO, et al. The Long-Term, Prospective, Therapeutic Impact of Cannabis on Post-Traumatic Stress Disorder. Cannabis and Cannabinoid Research, 2022. Disponível em:
5. CALLÉN L, et al. Cannabinoid Receptors CB1 and CB2 Form Functional Heteromers in Brain. Journal of Biological Chemistry, 2012. Disponível em:
6. CARCUTE D e LINHARES M. Boletins: Monitoramento Pós-Mercado. Disponível em:
7. CASARETT DJ, et al. Benefit of Tetrahydrocannabinol versus Cannabidiol for Common Palliative Care Symptoms. Journal of palliative medicine, 2019; 22(10): 1180–1184.
8. DE FARIA SM, et al. Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease. Journal of psychopharmacology , 2020; 34(2): 189–196.
9. FEINGOLD D, et al. Depression and anxiety among chronic pain patients receiving prescription opioids and medical marijuana. Journal of affective disorders, 2017; 218: 1–7.
10. GILMAN JM, et al. Effect of Medical Marijuana Card Ownership on Pain, Insomnia, and Affective Disorder Symptoms in Adults: A Randomized Clinical Trial. JAMA network open, 2022; 5(3): e222106.
11. GOPALAKRISHNA G, et al. Cannabinoids in the management of frontotemporal dementia: a case series. Neurodegenerative disease management, 2021; 11(1): 61–64.
12. HAUG NA, et al. Cannabis use patterns and motives: A comparison of younger, middle-aged, and older medical cannabis dispensary patients. Addictive behaviors, 2017; 72: 14–20.
13. HÄUSER W, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. European journal of pain , 2018; 22(9): 1547–1564.
14. KLUGER BM, et al. Cannabinoids in movement disorders. Parkinsonism & related disorders, 2022; 102: 124–130.
15. KUHARIC DB, et al. Cannabinoids for the treatment of dementia. Cochrane Database of Systematic Reviews, 2021. Disponível em:
16. KVITLAND LR, et al. Duration of untreated illness in first-treatment bipolar I disorder in relation to clinical outcome and cannabis use. Psychiatry research, 2016; 246: 762–768.
17. LADINO LD, et al. Medicinal Marijuana for Epilepsy: A Case Series Study. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2014. Disponível em:
18. LAND MH, et al. Effect of Cannabidiol on the Long-Term Toxicity and Lifespan in the Preclinical Model Caenorhabditis elegans. Cannabis and Cannabinoid Research, 2021. Disponível em:
19. LAWS JS e SMID SD Evaluating Cannabis sativa L.’s neuroprotection potential: From bench to bedside. Phytomedicine, 2022. Disponível em:
20. LEVY C, et al. Cannabis for Symptom Management in Older Adults. The Medical clinics of North America, 2020; 104(3): 471–489.
21. LI H, et al. Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer’s disease. European Journal of Medicinal Chemistry, 2020. Disponível em:
22. LOU K, et al. Cannabinoids for the treatment of refractory neuropathic pruritus in amyotrophic lateral sclerosis: A case report. Palliative Medicine, 2022. Disponível em:
23. NUGENT SM, et al. The Effects of Cannabis Among Adults With Chronic Pain and an Overview of General Harms. Annals of Internal Medicine, 2017. Disponível em:
24. PANDELIDES Z, et al. Developmental exposure to cannabidiol (CBD) alters longevity and health span of zebrafish (Danio rerio). GeroScience, 2020; 42(2): 785–800.
25. PANTOJA-RUIZ C, et al. Cannabis and pain: a scoping review. Brazilian Journal of Anesthesiology (English Edition), 2022. Disponível em:
26. PEBALL M, et al. Non-Motor Symptoms in Parkinson’s Disease are Reduced by Nabilone. Annals of neurology, 2020; 88(4): 712–722.
27. ROUND JM, et al. Changes in patient health questionnaire (PHQ-9) scores in adults with medical authorization for cannabis. BMC Public Health, 2020. Disponível em:
28. SACHEDINA F, et al. Medical cannabis use in Canada and its impact on anxiety and depression: A retrospective study. Psychiatry research, 2022; 313: 114573.
29. SHANNON S, et al. Cannabidiol in Anxiety and Sleep: A Large Case Series. The Permanente journal, 2019; 23: 18–041.
30. SHELEF A, et al. Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study. Journal of Alzheimer’s disease: JAD, 2016; 51(1): 15–19.
31. SOMMER DM, et al. Trends in the Medical Use of Synthetic Cannabinoids Among Older Adults in Ontario, Canada. Annals of internal medicine, 2020; 173(7): 589–591.
32. SURAEV AS, et al. An Australian nationwide survey on medicinal cannabis use for epilepsy: History of antiepileptic drug treatment predicts medicinal cannabis use. Epilepsy & behavior: E&B, 2017; 70: 334–340.
33. URBI B, et al. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial. BMJ open, 2019; 9(11): e029449.
34. VELZEBOER R, et al. Cannabis dosing and administration for sleep: a systematic review. Sleep, 2022; 45(11).
35. WANG Z, et al. Cannabidiol induces autophagy and improves neuronal health associated with SIRT1 mediated longevity. GeroScience, 2022. Disponível em:
36. 35.WATT G e KARL T. In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer’s Disease. Frontiers in Pharmacology, 2017. Disponível em:
37. 36.ZLOCZOWER, O. et al. Risk and benefit of cannabis prescription for chronic non-cancer pain. Journal of Addictive Diseases, 2022. Disponível em: